AMEX:DXR

Stock Analysis Report

Executive Summary

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Risks

  • Daxor is covered by less than 3 analysts.

Share Price & News

How has Daxor's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.1%

AMEX:DXR

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

90.0%

AMEX:DXR

9.1%

US Medical Equipment

2.0%

US Market

DXR outperformed the Medical Equipment industry which returned 8.7% over the past year.

DXR outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

DXRIndustryMarket
7 Day4.1%-0.9%1.3%
30 Day7.4%0.7%3.9%
90 Day9.1%4.4%3.4%
1 Year90.0%90.0%10.0%9.1%4.2%2.0%
3 Year18.5%17.3%70.7%65.5%47.2%37.6%
5 Year48.2%45.3%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Daxor's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Daxor undervalued based on future cash flows and its price relative to the stock market?

180.38x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Daxor to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Daxor to establish if it is available at substantial discount.


Price Based on Earnings

Daxor is overvalued based on earnings compared to the US Medical Equipment industry average.

Daxor is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Daxor is poor value based on expected growth next year.


Price Based on Value of Assets

Daxor is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Daxor expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

95.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Daxor's revenue is expected to grow significantly at over 20% yearly.

Daxor's earnings are expected to grow significantly at over 20% yearly.

Daxor's revenue growth is expected to exceed the United States of America market average.

Daxor's earnings growth is expected to exceed the United States of America market average.

Daxor's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Daxor will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Daxor performed over the past 5 years?

38.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Daxor has delivered over 20% year on year earnings growth in the past 5 years.

Daxor has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Daxor has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

Daxor has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Daxor used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Daxor's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Daxor's financial position?


Financial Position Analysis

Daxor is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Daxor's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Daxor's level of debt (32.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (67.6% vs 32.3% today).

Operating cash flow is negative therefore debt is not well covered.

Interest payments on debt are not well covered by earnings (EBIT is 0.6x annual interest expense, ideally 3x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.1x debt.


Next Steps

Dividend

What is Daxor's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Daxor's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Daxor's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Daxor has not reported any payouts.

Unable to verify if Daxor's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Daxor has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Daxor's salary, the management and board of directors tenure and is there insider trading?

1.1yrs

Average management tenure


CEO

Michael Feldschuh (50yo)

3yrs

Tenure

US$100,000

Compensation

Mr. Michael Richard Feldschuh has been the Chief Executive Officer and President of Daxor Corp. since September 21, 2016. Mr. Feldschuh served as Acting Chief Executive Officer and President of Daxor Corp. ...


CEO Compensation Analysis

Michael's remuneration is lower than average for companies of similar size in United States of America.

Michael's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.1yrs

Average Tenure

54yo

Average Age

The average tenure for the Daxor management team is less than 2 years, this suggests a new team.


Board Age and Tenure

7.7yrs

Average Tenure

77yo

Average Age

The tenure for the Daxor board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$9,76522 Mar 19
Robert Michel
EntityIndividual
Role
Chief Financial Officer
CFO, Chief Compliance Officer & Corporate Secretary
Shares750
Max PriceUS$13.02
BuyUS$14,81822 Mar 19
Michael Feldschuh
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares1,200
Max PriceUS$12.40
BuyUS$18,55008 Nov 18
Robert Michel
EntityIndividual
Role
Chief Financial Officer
CFO, Chief Compliance Officer & Corporate Secretary
Shares2,500
Max PriceUS$7.42

Ownership Breakdown


Management Team

  • Michael Feldschuh (50yo)

    Chairman

    • Tenure: 3yrs
    • Compensation: US$100.00k
  • Guido Manzo

    Vice President of Sales

    • Tenure: 0.7yrs
  • Bob Michel (62yo)

    CFO, Chief Compliance Officer & Corporate Secretary

    • Tenure: 1yrs
  • Jonathan Feldschuh (54yo)

    Chief Scientific Officer & Director

    • Tenure: 2.6yrs
    • Compensation: US$127.92k
  • Kathryn Kornafel

    Vice President of Marketing & Commercial Development

    • Tenure: 1.3yrs

Board Members

  • Phil Frost (83yo)

    Chairman of Medical Advisory Board

    • Tenure: 0yrs
  • James Lombard (85yo)

    Independent Director

    • Tenure: 30.7yrs
    • Compensation: US$2.50k
  • Martin Wolpoff (77yo)

    Independent Director

    • Tenure: 30.7yrs
    • Compensation: US$2.50k
  • Michael Feldschuh (50yo)

    Chairman

    • Tenure: 3yrs
    • Compensation: US$100.00k
  • Bernhard Saxe (84yo)

    Director

    • Tenure: 11.7yrs
    • Compensation: US$2.50k
  • Jonathan Feldschuh (54yo)

    Chief Scientific Officer & Director

    • Tenure: 2.6yrs
    • Compensation: US$127.92k
  • Fred Gilbert

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • James Brassel

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Ed Feuer (63yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$2.50k

Company Information

Daxor Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Daxor Corporation
  • Ticker: DXR
  • Exchange: AMEX
  • Founded: 1970
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$35.595m
  • Shares outstanding: 3.75m
  • Website: https://www.daxor.com

Location

  • Daxor Corporation
  • Empire State Building
  • Suite 7120
  • New York
  • New York
  • 10118
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DXRAMEX (NYSE MKT LLC)YesCommon StockUSUSDJan 1975

Biography

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 23:34
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.